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Abstract
Background: WR1065 is the free-thiol metabolite of the cytoprotective aminothiol amifostine, which is used clinically
at very high doses to protect patients against toxicity induced by radiation and chemotherapy. In an earlier study we
briefly reported that the aminothiol WR1065 also inhibits HIV-1 replication in phytohemagglutinin (PHA)-stimulated
human T-cell blasts (TCBs) infected in culture for 2 hr before WR1065 exposure. In this study we expanded the original
observations to define the dose-response curve for that inhibition, and address the question of additive effects for the
combination of WR1065 plus Zidovudine (AZT). Here we also explored the effect of WR1065 on SIV by examining TCBs
taken from macaques with well-established infections several months with SIV.
Results: TCBs from healthy human donors were infected for 2 hr with HIV-1, and viral replication (p24) was measured
after 72 hr of incubation with or without WR1065, AZT, or both drugs. HIV-1 replication, in HIV-1-infected human
TCBs, was inhibited by 50% at 13 μM WR1065, a dose at which 80% of the cells were viable. Cell cycle parameters were
the same or equivalent at 0, 9.5 and 18.7 μM WR1065, showing no drug-related toxicity. Combination of AZT with
WR1065 showed that AZT retained antiretroviral potency in the presence of WR1065. Cultured CD8+ T cell-depleted
PHA-stimulated TCBs from Macaca mulatta monkeys chronically infected with SIV were incubated 17 days with WR1065,
and viral replication (p27) and cell viability were determined. Complete inhibition (100%) of SIV replication (p27) was
observed when TCBs from 3 monkeys were incubated for 17 days with 18.7 μM WR1065. A lower dose, 9.5 μM
WR1065, completely inhibited SIV replication in 2 of the 3 monkeys, but cells from the third macaque, with the highest
viral titer, only responded at the high WR1065 dose.
Conclusion: The study demonstrates that WR1065 and the parent drug amifostine, the FDA-approved drug Ethyol,
have antiretroviral activity. WR1065 was active against both an acute infection of HIV-1 and a chronic infection of SIV.
The data suggest that the non-toxic drug amifostine may be a useful antiretroviral agent given either alone or in
combination with other drugs as adjuvant therapy.
Published: 6 November 2009
AIDS Research and Therapy 2009, 6:24 doi:10.1186/1742-6405-6-24
Received: 15 October 2009
Accepted: 6 November 2009
This article is available from: http://www.aidsrestherapy.com/content/6/1/24
© 2009 Poirier et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.AIDS Research and Therapy 2009, 6:24 http://www.aidsrestherapy.com/content/6/1/24
Page 2 of 10
(page number not for citation purposes)
Background
Highly Active Antiretroviral Therapy (HAART) has revolu-
tionized the treatment of HIV-1 disease and is primarily
responsible for substantial improvements in the survival
of HIV-1-infected patients seen in the last decade. How-
ever, the search for development of novel antiretroviral
agents is ongoing and is largely driven by issues relating to
drug resistance, formulation of drug combinations, phar-
macokinetic profiles and toxicity. For example, combina-
tions of nucleoside reverse transcriptase inhibitors
(NRTIs) widely used in adult disease and for the preven-
tion of maternal-fetal HIV-1 transmission have been
instrumental in prolonging the lives of adults and saving
the lives of thousands of children [1-4]. However, concern
regarding mitochondrial and other toxicities in adults
[5,6] and in HIV-1-uninfected children exposed in utero
[7-9] to antiretroviral drugs has underscored the impor-
tance of designing strategies to both complement current
antiretroviral cocktails and attenuate their toxic proper-
ties.
Amifostine [H2N(CH2)3NH(CH2)2S(PO3H2)], the FDA-
approved drug Ethyol http://www.ethyol.com/ is an
organic thiophosphate that is dephosphorylated in vivo to
the reduced free thiol WR1065 [H2N-(CH2)3NH-
(CH2)2SH]. Amifostine inhibits radiation-induced muta-
genesis in human [10] and hamster [11] cell lines.
WR1065 selectively protects normal tissues, but not
tumors, against ionizing radiation damage and chemo-
therapeutic drug cytotoxicity [12-14]. This compound has
multiple biological activities, including ability to: detoxify
reactive metabolites of chemotherapeutic agents; scavenge
free radicals; modulate apoptosis; alter gene expression;
and up-regulate mitochondrial manganese-superoxide
dismutase [12,15].
Other thiols [16-18], and an analog of WR1065 [19], were
reported to have antiretroviral activity. In addition, we
showed in a pilot study that WR1065, the active free thiol
metabolite, inhibits HIV-1 replication [20]. The cell cul-
ture studies presented here, using HIV-1 and the Simian
Immunodeficiency Virus (SIV), are important preliminary
steps towards our ultimate goal of evaluating the clinical
efficacy of amifostine as an antiretroviral, or adjuvant-
antiretroviral and/or adjuvant agent. In vitro studies are
limited to the use of WR1065 because cells typically lack
the alkaline phosphatase that is required to activate ami-
fostine. Here we present: 1) the dose-response relation-
ship for WR1065 antiretroviral activity in HIV-1-infected
human T-cell blasts (TCBs) in the absence and presence of
AZT; and 2) the antiretroviral effects of WR1065 in cul-
tured TCBs from macaques infected chronically (14
months) with SIV.
Methods
Drug exposure and evaluation of virus replication in 
human T-cell blasts (TCBs)
Fresh human peripheral blood mononuclear cells (PBMC,
from the NIH Transfusion Center) were cultured in 250
ml flasks (2 × 106 cells/ml) for 48 hr in RPMI-1640 media
(ATCC, Manassas, VA) containing 10% fetal bovine serum
(Hyclone, Logan, UT), 1% penicillin/streptomycin/
glutamine (Invitrogen, Gaithersburg, MD), 10 U/ml inter-
leukin 2 (IL2, BD Biosciences, San Jose, CA) and 20 μg/ml
phytohemagglutinin (PHA, Sigma, St. Louis, MO). After
48 hr, the cells were washed to remove PHA and the
resulting PHA-stimulated T-cell blasts (human TCBs)
were transferred to 96 well microtiter plates (0.5 × 106
cells/well), infected with HIV-1BZ-167(gift from S. Sharpe,
New York University, New York, NY) at 170-200 50% tis-
sue culture infectious dose/105 target cells for 2 hr, and
subsequently incubated with 2.5-103.0 μM WR1065
(Chemical Carcinogen Reference Standard Repository,
Kansas City, MO) and/or 0.002-0.117 μM AZT (Sigma-
Aldrich Inc., St. Louis, MO) for 72 hr. Cells were then har-
vested and evaluated for HIV-1 replication by RETRO-TEK
HIV-1 p24 Extended Range Elisa Kit (ZeptoMetrix, Buf-
falo, NY) or by HIV-1 p24 Antigen Capture Assay Kit (Bio-
logical Products Laboratory, FCRDC, Frederick, MD).
To compare the metabolite WR1065 with the parent com-
pound amifostine, in one experiment 50.0 μM amifostine
(Chemical Carcinogen Reference Standard Repository)
was added. Due to the lack of alkaline phosphatase in cul-
tured human cells, we pre-incubated the amifostine with
alkaline phosphatase (Sigma-Aldrich Inc.), at 1 U per 100
μl of media containing 50 μM amifostine, to generate
WR1065. In experiments designed to examine virus repli-
cation with the combination of AZT and WR1065, the
standard curve for AZT included concentrations between
0 and 23.0 ηM and WR1065 was used at either 18.7 or
26.0 μM.
Cell survival of human TCBs
Drug-induced cell viability at 72 hr was determined by
Trypan blue exclusion [20,21] in human TCBs grown in a
second 96-well microtiter plate, where cells were exposed
to drugs in the absence of HIV-1 inoculation. Cells from
triplicate wells were mixed with Trypan blue and counted
twice by hemocytometer. Numbers of viable (unstained)
cells were expressed as a percentage of total (stained plus
unstained) cells.
To examine apoptosis as a measure of cell viability in
human TCBs infected with HIV-1 and treated with drug,
we assayed for Annexin V (as previously described [22]).
Cells taken from the wells used for p24 protein analysis
were subjected to flow cytometry for this analysis andAIDS Research and Therapy 2009, 6:24 http://www.aidsrestherapy.com/content/6/1/24
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sorted on the basis of Annexin V positivity (apoptotic)
and negativity (non-apoptotic).
Flow Cytometry for determination of cell cycle parameters 
in human TCBs cultured in the presence of WR1065
Flow cytometry was used to evaluate the integrity of cell
cycle parameters in human TCBs exposed to 0, 9.5 and
18.7  μM WR1065 according to the protocol described
above. Harvested cells were pelleted and washed with cul-
ture media without serum before they were fixed over-
night in 1 ml of ice-cold 70% ethanol, pelleted by
centrifugation and incubated with Ribonuclease A
(Sigma-Aldrich Inc.) at room temperature for 20 min. Pro-
pidium iodide (20-50 μg/ml) (Molecular Probes, Eugene,
OR) was added to each cell suspension and cells were kept
in the dark at 4°C overnight. Cells were passed through a
fluorescence activated flow cytometer (FACSCalibur, BD
Biosciences, San Jose, CA) using the doublet discrimina-
tion module, and data were acquired using CellQuest (BD
Biosciences) software. Cell cycle analysis was performed
using ModFit software (Venty Software, Topsham, ME).
Percentages of cells in G0-G1, S and G2-M phases were cal-
culated directly by the software.
Culture of SIV-infected macaque TCBs and exposure to 
WR1065
Blood used to prepare macaque PBMC was collected from
Macaca mulatta monkeys (macaques) numbered M612,
M642 and M674. The macaques, housed at Advanced Bio-
Science Laboratories (ABL), Inc. (Rockville, MD), had
been infected with SIVMac251 for 14 months before these
experiments were performed. The animals were main-
tained and treated under conditions approved by the
Association for Assessment and Accreditation of Labora-
tory Animal Care, and all procedures were performed in
accordance with humane principles for laboratory animal
care. Protocols were reviewed and approved by the Insti-
tutional Animal Care and Use Committee of ABL, Inc.
Macaque PBMC (106  cells/ml), prepared from blood
using Ficoll gradient centrifugation, were depleted of
CD8+ cells by magnetic bead separation using the CD8
Microbead Kit for non-human primates (Miltenyi,
Auburn, CA). Briefly, whole PBMC were incubated with
microbeads conjugated to an anti-CD8+ antibody and
then washed. Cells were resuspended in Dulbecco's phos-
phate buffered saline (DPBS, Invitrogen, Carlsbad, CA)
supplemented with 5% bovine serum albumin (BSA) and
2 mM EDTA, and run through a magnetic column. The
flow-through material contained PBMC depleted (>99%)
of CD8+ T-cells, which were then counted and cultured
using the same media as for the human TCBs (above).
Once in culture, PBMC were incubated for 48 hr in the
presence of PHA to activate remaining T-cells, as described
above for human TCBs. These cells, macaque CD8+ T cell-
depleted, PHA-stimulated macaque T-cell blasts (TCBs)
were transferred to 48-well plates (500 μL media/well, 0.5
× 106 cells/well, 6 wells/macaque) and cultured for an
additional 17 days in the presence of 0, 9.5 or 18.7 μM
WR1065. The medium was changed twice weekly for a
total of 4 times, and fresh WR1065 was added at each
medium change. Cell survival was evaluated on days 10
and 17 using the Cell Titer 96® Aqueous Non-Radioactive
Cell Proliferation (MTS) Assay (Promega Corp., Madison,
WI). SIV levels were assayed using the p27 Antigen Assay
kit (Beckman Coulter, Fullerton, CA) on days 3, 7, 10, 14
and 17.
Results
Anti-HIV-1 activity and cytotoxicity of WR1065 in human 
TCBs
In HIV-1-infected human TCBs, the HIV-1 titers, deter-
mined in the absence of drug, ranged from 1,312 to
38,000 pg p24/ml (10,205 ± 2,367, mean ± SE, n = 19
experiments). The inter-experimental variability, likely a
reflection of the variability of HIV-1 growth in cells from
different individuals, was such that we chose to present
"% Inhibition" in the graphs and tables to take advantage
of the power of multiple experiments. We assayed for
WR1065-induced inhibition of HIV-1 replication at three
points on the dose-response curve in several replicate
experiments. The HIV-1 inhibition data are shown in
Table 1, where 26 and 52 μM WR1065 gave 65% and 89%
inhibition of HIV-1, respectively. Parallel cell survival
studies were performed using either Trypan blue exclusion
in cells with drug but no virus, or Annexin V, an early
marker of apoptosis, in the HIV-1-infected cells contain-
ing drug (Table 1). Because the Trypan blue assay showed
extensive cell death at 52 and 103 μM WR1065, we chose
to perform subsequent experiments at ≤ 26 μM WR1065.
For the Annexin V assay, drug-exposed cultures ranged
from 75% to 100% Annexin V-negative (non-apoptotic),
with the majority of experiments showing 85-95% of the
cells as Annexin-V negative (data not shown).
Table 1 also presents mean values for replicate experi-
ments in which we exposed HIV-1-infected human TCBs
to amifostine to compare the anti-HIV-1 activity of this
compound with its active metabolite WR1065. Because
cultured human cells lack alkaline phosphatase, we pre-
incubated 50 μM amifostine with this enzyme for 30 min-
utes before adding the mixture to HIV-1-infected human
TCBs to evaluate viral replication. The extent of HIV-1
inhibition and the fraction of cells surviving were similar
to those observed in cells cultured with 52 μM WR1065
(Table 1), indicating that most of the amifostine had been
converted to WR1065 and was available to inhibit virus
replication.AIDS Research and Therapy 2009, 6:24 http://www.aidsrestherapy.com/content/6/1/24
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Complete dose-response curves for % inhibition of HIV-1
replication with WR1065, and TCB % survival determined
by Trypan blue are plotted in Figure 1A (mean ± SE, n = 4
experiments). The concentration of WR1065 giving 50%
inhibition of virus replication was 13 μM, and at this dose
the TCBs were 80% viable by the Trypan blue. Also by
Trypan blue, 50% cell survival was observed at 52 μM
WR1065, yielding a therapeutic index of 0.25 for the cell
culture studies. However, this relatively-poor in vitro ther-
apeutic index is not relevant for the in vivo potential
because the parent drug amifostine can be administered at
very high doses with virtually no toxicity (see Discussion).
As an additional test of WR1065-induced toxicity, flow-
cytometric analysis of cell cycle parameters, was per-
formed using human TCBs grown in the presence of 0, 9.5
and 18.7 μM WR1065. Table 2 shows values for percent-
age of cells in S-phase, G2/M-phase and G0/G1 phase. We
found that exposures of human TCBs to 9.5 and 18.7 μM
WR1065 did not significantly alter the TCB cycling, as
compared to unexposed cells, adding support to the
notion that the TCBs did not sustain unacceptable toxicity
at the doses chosen.
Anti-HIV-1 activity of AZT, with and without WR1065, in 
human TCBs
Figure 1B shows inhibition of HIV-1-replication, and cell
survival determined by Trypan blue, for AZT dose-
response experiments (mean ± SE, n = 4 experiments). The
figure shows 50% inhibition of virus replication at 5.0 ηM
AZT, a dose that was associated with 90% cell survival.
We performed three experiments to examine inhibition of
HIV-1 replication with the combination of AZT and
WR1065 (Table 3). In each experiment, we compared two
AZT dose-response curves, one with increasing doses of
AZT alone, and a second with identical concentrations of
AZT plus a constant amount of WR1065 added to each
well. A representative experiment is shown in Figure 2, in
which the increase in % inhibition of virus replication
with both AZT and WR1065 is evident by comparing the
curves with AZT alone (solid diamond) and AZT plus
WR1065 (solid square). In this experiment (Experiment 3
from Table 3) the only dose of AZT that gave less-than-sat-
urating inhibition of HIV-1 replication was 2.2 ηM. This
AZT dose was informative because it did not saturate virus
inhibition, allowing for further inhibition when WR1065
was added (see Table 3, right column). Due in part to
interindividual differences in growth, HIV-1 infection
capacity, and specific drug dose used, variability was such
that the experiments could not be combined. However,
the consistent increase in the % inhibition of HIV-1 repli-
cation with the addition of WR1065 to non-saturating
doses of AZT (see Table 3, right column) suggests that
WR1065 did not inhibit the antiretroviral activity of AZT.
On the contrary, combination of WR1065 with AZT did
increase the antiretroviral efficacy of AZT.
Anti-SIV activity of WR1065 in TCBs from SIV-infected 
macaques
TCBs from three macaques, which had been chronically
infected with SIV for 14 months, were used to test the
effect of WR1065 on SIV replication ex vivo. At the time of
blood collection, the animals (612, 642 and 674), had
plasma titers of 0.10, 0.03 and 6.40 × 106 copies of SIV
RNA/ml, and CD4 counts of 376, 635 and 547/ul, respec-
tively. The PBMC were depleted of CD8+ T cells, PHA stim-
ulated, and either cultured for 20 days in the absence of
WR1065, or cultured for 3 days before the addition of 0,
9.5 or 18.7 μM WR1065 to the medium, and then for an
additional 17 days. The medium was changed twice
weekly in both culture groups and fresh WR1065 was
added at each medium change. Using the MTS assay, cell
survival was measured on days 10 (data not shown) and
17 of this experiment (Table 4).
Kinetic p27 data, generated in the cultures with and with-
out WR1065, are illustrated in Figure 3. SIV replication by
TCBs from macaque 612 (Figure 3A) cultured in the
absence of WR1065 (solid triangle) peaked at day 10. In
Table 1: Inhibition of HIV-1 replication in human TCBs by WR1065 and amifostine.
Concentration (μM) Number of experiments % Inhibition ofa HIV-1 
replication (mean ± SE)
% Viabilityb no HIV-1 
Infection (Trypan blue)
% Viabilityc HIV-1 Infec-
tion (Annexin V)
WR1065
26 5 65.0 ± 7.5 77.8 ± 4.2 95.8 ± 0.5
52 7 88.7 ± 5.5 49.3 ± 3.8 92.5 ± 1.1
103 8 93.9 ± 3.1 36.8 ± 17.1 NDd
Amifostine
50 4 75.4 ± 8.3 53.2 ± 9.6 NDd
a Human TCBs were infected with HIV-1 for 2 hr before incubation for 72 hr with WR1065, or amifostine converted to WR-1965 by pre-
incubation with alkaline phosphatase. 50% inhibition of virus replication was at 13 μM WR1065.
b Cell viability (mean ± SE), in HIV-1-uninfected cells, as determined by Trypan blue exclusion.
c Cell viability (mean ± range, n = 2 experiments), in HIV-1-infected cells, was determined by Annexin V.
dND = not determined.AIDS Research and Therapy 2009, 6:24 http://www.aidsrestherapy.com/content/6/1/24
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(A) Concentration-dependent dose-response curve for % Inhibition (mean ± SE, n = 4 experiments) of HIV-1 replication in  human TCBs incubated with 2.5, 13.0, 26.0, 51.5, 103.0 and 206.0 μM WR1065 for 72 hr and assayed by p24 ELISA (solid trian- gle) Figure 1
(A) Concentration-dependent dose-response curve for % Inhibition (mean ± SE, n = 4 experiments) of HIV-1 
replication in human TCBs incubated with 2.5, 13.0, 26.0, 51.5, 103.0 and 206.0 μM WR1065 for 72 hr and 
assayed by p24 ELISA (solid triangle). Cell survival (mean ± SE, n = 4 experiments) determined by Trypan blue exclusion 
(solid square). (B) Concentration dependent dose-response curve for HIV-1 replication in human TCBs incubated with 1.9, 
3.7, 7.3, 11.7, 29.3 and 117.0 ηM AZT for 72 hr and assayed by p24 ELISA (solid triangle). Cell survival (mean ± SE, n = 4 
experiments) determined by Trypan blue exclusion (solid square).
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contrast, SIV replication was reduced approximately 5-
fold, to background levels, in the two groups exposed to
WR1065 (solid square, hollow diamond) (Figure 3A). The
peak virus titer in the macaque 612 TCBs (5200 pg SIV/ml
at 10 days) was the lowest of those examined. In TCBs
from macaque 642 (Figure 3B), at 7 days, the SIV p27 lev-
els in groups exposed to 0 (solid triangle) and 9.5 (solid
square) μM WR1065 were measurable, and only in cells
exposed to 18.7 μM WR1065 (hollow diamond) was the
SIV titer lowered to background levels. At 7 days, TCBs
cultured from macaque 642 had a virus titer of 30,000 pg
SIV/ml (Figure 3B), which was much higher than the SIV
titers for the other two macaques. Perhaps because of this,
an antiviral effect was observed only at the 18.7 μM
WR1065 dose in TCBs from macaque 642. In untreated
TCBs from macaque 674 (Figure 3C), the virus titer (solid
triangle) showed two viral peaks, one at day 7, followed
by a decline at day 10, and a second increase for the
remainder of the experiment. WR1065-exposed cells
(solid square, hollow diamond) from this animal had
baseline SIV levels throughout the 17 day culture period,
indicating a persistent WR1065-induced inhibition of SIV
replication. This inhibition was observed irrespective of
fluctuations in the SIV replication pattern found in
untreated cultures from different animals.
In summary, these ex vivo experiments performed using
macaque TCBs obtained from three chronically-infected
macaques demonstrate that WR1065 effectively inhibited
production of SIV p27 throughout the 17-day culture
period. Furthermore, our finding that 18.7 μM WR1065
was required to inhibit SIV replication in cultures with the
highest SIV levels (Figure 3B) suggests that the inhibition
of SIV replication is dose dependent.
Discussion
These experiments demonstrate that WR1065 is effective
in significantly reducing HIV-1 replication in cultured
human TCBs infected with HIV-1 for 2 hr prior to treat-
ment, and in macaque TCBs cultured from SIV-infected
macaques for 17 days with the addition of WR1065.
Taken together, these studies show inhibition of replica-
tion of two distinct retroviruses in TCBs from two differ-
ent primate species. The data suggest that the parent drug,
amifostine, which is non-toxic when used at very high
doses  in vivo, may have clinical utility. In addition, in
combination studies using both AZT and WR1065 in
human TCBs, we found that addition of WR1065 to a
non-saturating dose of AZT resulted in more effective
inhibition of HIV-1 replication than was observed with
AZT alone, suggesting that amifostine might also be useful
as supplementary or adjuvant therapy.
In a previous manuscript [20] we reported three pilot
experiments using HIV-1, AZT and WR1065. The WR1065
doses used for those studies were very high (up to 1000
μM), and in only one of the three experiments did the
dose range extend below 100 μM WR1065. Therefore,
more information was required to determine the feasibil-
ity of initiating studies in primates. The experiments pre-
sented in this manuscript are essential because they define
the dose-response parameters and show consistency in
HIV-1 inhibition for >20 experiments. In addition, in this
study the cytotoxicity was carefully defined in cell cycle
Table 2: WR1065 did not alter cell cycle parameters in HIV-1-uninfected human TCBs at non-toxic doses.a
WR1065 (μM) % Cells in S Phase % Cells in G2/M Phase % of Cells in G0/G1 Phase
0 5.3 ± 1.6 1.3 ± 0.6 93.8 ± 2.2
9.5 6.2 ± 2.6 1.3 ± 0.7 92.5 ± 3.2
18.7 8.3 ± 2.5 1.5 ± 0.5 90.5 ± 2.6
a Fresh human TCBs were infected with HIV-1 for 2 hr before incubation for 72 hr with WR1065. Values shown are mean ± range (n = 2). Cell 
viability, as determined by Trypan blue exclusion was 84.4-87.4% (mean ± range, n = 2).
Human TCB dose-response curves for: AZT alone (solid dia- mond, 0 -29.3 ηM); and the same doses of AZT with 18.7 μM  WR1065 added to each dose (solid square) Figure 2
Human TCB dose-response curves for: AZT alone 
(solid diamond, 0 -29.3 ηM); and the same doses of 
AZT with 18.7 μM WR1065 added to each dose (solid 
square). Note that WR1065 alone inhibited HIV-1 replica-
tion, and when WR1065 was added to 2.2 ηM AZT, the % 
inhibition of HIV-1 replication increased by 50%; high doses 
of AZT that completely inhibit virus replication were not 
informative.
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and other experiments that were not performed previ-
ously. Finally, if amifostine is to be evaluated for use in
humans it is important to show evidence of antiviral effi-
cacy in SIV-infected macaques, and the in vitro studies pre-
sented here are a necessary a first step in the process.
Whereas amifostine has little or no toxicity in the clinic,
WR1065 was cytotoxic in our cell cultures. This may have
occurred partially as a result of the formation of WR1065
disulfide metabolites and other compounds. In long-term
experiments this cytotoxicity can be prevented by the
addition of aminoguanidine to the culture media [23].
However, because of the short duration of our human
TCB studies we chose not to use aminoguanidine, and we
lowered the WR1065 dose to ≤ 26 μM to obtain accepta-
ble cell survival. Whereas the role of aminothiol oxidative
metabolites may be critical for the interpretation of the
cell culture studies, toxic metabolites do not appear to be
an issue in vivo when amifostine is given. Additional
experiments will be required to determine the in vivo effi-
cacy of this drug.
The experiments in which AZT and WR1065 were given
together were designed to investigate whether the antiviral
efficacy of AZT might be inhibited in the presence of
WR1065. The four experiments presented in Table 3 all
showed that AZT was active in the presence of WR1065. In
addition they suggested that there might be synergism in
antiretroviral capacity when the drugs were combined,
because for the informative doses, the AZT % Inhibition
of HIV-1 replication was increased when WR1065 was
added. This is an intriguing pilot finding, which requires
much more detailed experimentation and statistical anal-
ysis for confirmation.
Amifostine, when dephosphorylated to WR1065, has
cytoprotective activity that appears to be related both to
the free thiol group and to the disulfide formed by inter-
action of the two WR1065 free thiol groups [13]. These
aminothiol metabolites compete with polyamines to alter
gene expression, stabilize DNA by electrostatic intercala-
tion [12], act as free radical scavengers by binding to NFκB
and p53 [24,25], thereby increasing transactivation of
downstream genes, including manganese superoxide dis-
mutase (MnSOD)[15]. WR1065 inhibits the catalytic site
of Topoisomerase II [15] and up-regulates p21 [26,27].
Both of these genes are involved in cell cycle arrest and are
relevant to the finding that WR1065-induced cytoprotec-
tion requires an intact and functioning DNA repair mech-
anism [12].
Amifostine is used at high doses to protect against the
lethality of radiotherapy and chemotherapy in adults
[28], and in pediatric oncology [29-31]. The recom-
mended daily amifostine dose is 910 mg/M2, but higher
doses are tolerated, and up to 2700 mg/M2 has been used
in children [32-34]. Pharmacokinetic studies, performed
in humans and in monkeys [30,33,34], showed that
administration of amifostine is followed by rapid dephos-
phorylation to WR1065, slower elimination of WR1065,
and formation of various longer-lived metabolites. In one
pharmacokinetic study, in children given 825 mg amifos-
tine/M2, the peak concentration of WR1065 in whole
blood, plasma and blood cells was 75, 85 and 83 μM,
respectively [30]. In cynomolgus monkeys given subcuta-
neous amifostine at 260 mg/M2, the WR1065 peak
plasma concentration was 104 μM [33]. In addition, bio-
availability after oral administration yielded metabolites
that persisted in the plasma for several hours [34]. The
Table 3: Increase in AZT-induced % Inhibition of HIV-1 replication by the addition of non-toxic doses of WR1065a
Expt. Number % HIV-1 Inhibition 
WR1065 alone 
(Concentration)
% HIV-1 Inhibition AZT 
alone (Concentration)
% HIV-1 Inhibition AZT 
+ WR1065
Increase in % inhibition 
HIV-1 with added WR1065 
a
16 5 . 2 %
(26.0 μM)
71.8%
(1.9 ηM)
86.6% 14.8%
22 0 . 0 %
(26.0 μM)
38.8%
(1.9 ηM)
61.4% 29.9%
36 7 . 4 %
(18.5 μM)
31.5%
(2.2 ηM)
81.9% 50.4%
a In each experiment two identical AZT standard curves for inhibition of virus replication were compared; one curve had 1.9-23.0 ηM AZT alone 
and the second curve had 1.9-23.0 ηM AZT plus a constant non-toxic amount (see table) of WR1065 added to each AZT concentration. The only 
informative concentrations of AZT were the 1.9 and 2.2 ηM doses that alone gave % Inhibition values well below 80%. A representative set of 
curves (experiment 3) including all points is shown in Figure 2.
Table 4: Cell viability (%) in CD8+ T cell-depleted TCBs, taken 
from 3 SIV-infected macaques, that were exposed to WR1065 
for 17 days in culture
WR1065 (μM) Monkey Number Mean ± SE
612 642 674
0 100 100 100 100.0 ± 0.0
9 . 5 7 67 48 47 8 . 0  ±  3 . 0
18.7 73 63 75 70.3 ± 3.7AIDS Research and Therapy 2009, 6:24 http://www.aidsrestherapy.com/content/6/1/24
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SIV replication in macaque TCBs obtained from SIV-infected animals and cultured with 0 (solid triangle), 9.5 (solid square) or  18.7 (hollow diamond) μM WR1065 for 17 days Figure 3
SIV replication in macaque TCBs obtained from SIV-infected animals and cultured with 0 (solid triangle), 9.5 
(solid square) or 18.7 (hollow diamond) μM WR1065 for 17 days. SIV p27 values are shown for days 7, 10, 14 and 17 
of culture for TCBs from macaques: (A) 612 (0.10 × 106 copies SIV/ml and 376 CD4 cells/ml); (B) 642 (0.03 × 106 copies SIV/
ml and 635 CD4 cells/ml); and (C) 674 (6.40 × 106 copies of SIV/ml and 547 CD4 cells/ml).
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ability to achieve plasma and in vivo intracellular WR1065
levels in the range of 100 μM suggests that it may be pos-
sible to dose HIV-1 infected patients with amifostine lev-
els that will sustain antiretroviral activity using FDA-
recommended doses of drug. If amifostine is shown to be
an effective clinical antiretroviral agent, it may be useful in
patients who have developed resistance to conventional
antiretroviral therapy, or as prophylaxis in HIV-1-unin-
fected health care workers who have been occupationally-
exposed to HIV-1.
The mechanism(s) that may contribute to the antiretrovi-
ral efficacy of these drugs are still largely a matter of con-
jecture. One possible explanation comes from the
importance of thiol-disulfide exchange in fusion of the
HIV-1 envelope with host cell membrane, a process facil-
itated by protein disulfide isomerase [35,36]. Inhibitors of
this enzyme prevent the establishment of virus infection.
Also, retroviral inactivation has been accomplished using
oxidizing agents that react with cysteine thiols in the zinc
finger motifs of the retroviral nucleocapsid proteins
[37,38]. The organic thiophosphate WR-151327, a meth-
ylated derivative of amifostine, inhibited HIV-1 reverse
transcriptase activity and prevented the production of
viral protein synthesis in a promonocytic cell line chroni-
cally-infected with HIV-1[19]. Inhibition of viral replica-
tion was maximal at 15 mM, a dose which exhibited no
cytotoxicity for up to 7 days in culture. Several mecha-
nisms, including modulation of glutathione, and NFκB-
dependent and -independent pathways, were speculated
to contribute to the observed inhibition of virus replica-
tion, and it is possible that those mechanisms may be rel-
evant to our experiments with WR1065[19].
Conclusion
The present study expands our original observation [23]
that WR1065 inhibits the replication of HIV-1, by estab-
lishing dose-response curves for WR1065 and AZT alone,
and showing that AZT has antiretroviral activity in the
presence of WR1065. Furthermore, in this study we exam-
ined the in situ effect of WR1065 in a second primate spe-
cies infected with an immunodeficiency virus inducing
AIDS-like symptoms, and demonstrated that WR1065
inhibits SIV replication in TCBs activated from macaques
infected for 14 months with SIV. These studies do not elu-
cidate the underlying mechanisms of antiretroviral effi-
cacy, but they are consistent with previous reports of HIV-
1 and SIV replication inhibition induced by exposure of
cultured cells to thiol-disrupting agents, and they may
lead to useful supplementary and/or complementary clin-
ical approaches for the management of HIV-1. Amifostine
may have promise as an adjuvant antiretroviral agent
because: it is non-toxic in humans and can be used at very
high doses; human plasma levels can reach 50-100 μM,
concentrations shown in culture to inhibit viral replica-
tion; it is an anti-mutagen and not likely to exhibit typical
patterns of antiretroviral drug resistance involving muta-
genesis; and, structurally the molecule is reasonably sim-
ple allowing for relatively inexpensive chemical synthesis.
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